This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| COVID-19 | 326 |
| • | 312 |
| ICU | 297 |
| ARDS | 203 |
| Health | 168 |
| SARS | 162 |
| RCT | 137 |
| University | 132 |
| mg | 130 |
| Hospital | 122 |
| Investigator | 119 |
| X | 107 |
| SAE | 104 |
| CoV-2 | 102 |
| AE | 100 |
| du | 98 |
| Committee | 98 |
| Clinical | 93 |
| Research | 89 |
| le | 87 |
| COPD | 87 |
| BSC | 87 |
| BALANCE | 82 |
| Alexion | 80 |
| sargramostim | 79 |
| ou | 78 |
| Data | 76 |
| ravulizumab | 75 |
| VTE | 74 |
| National | 71 |
| kg | 70 |
| IL-6 | 69 |
| enoxaparin | 64 |
| Table | 64 |
| COVID | 64 |
| Protocol | 63 |
| Day | 63 |
| Trials | 63 |
| au | 63 |
| Medical | 61 |
| Fig | 61 |
| SAEs | 60 |
| GM | 60 |
| Ethics | 60 |
| sera | 59 |
| China | 59 |
| CTCAE | 56 |
| IV | 56 |
| TIRS | 56 |
| les | 56 |
| azithromycin | 56 |
| C | 55 |
| AEs | 54 |
| CRF | 53 |
| Australia | 52 |
| un | 50 |
| traitement | 50 |
| CSF | 49 |
| des | 49 |
| sarilumab | 47 |
| PCR | 47 |
| Study | 45 |
| Sponsor | 45 |
| Institute | 45 |
| April | 45 |
| Group | 44 |
| GCP | 43 |
| < | 42 |
| Les | 42 |
| l'étude | 41 |
| IU | 41 |
| IRB | 41 |
| DOI | 41 |
| Cancer | 41 |
| une | 40 |
| Global | 39 |
| Care | 39 |
| TCM | 39 |
| May | 39 |
| Patient | 38 |
| New | 38 |
| dans | 38 |
| UK | 38 |
| B | 37 |
| F | 36 |
| à | 35 |
| ± | 35 |
| Monitoring | 35 |
| LMWH | 35 |
| A | 35 |
| Safety | 35 |
| MV | 34 |
| LifeLab | 34 |
| Disease | 34 |
| Amendment | 34 |
| CPAP | 33 |
| Assessment | 33 |
| Jun | 33 |
| DMC | 33 |
| SOC | 33 |
| ≤ | 32 |
| promoteur | 32 |
| sha | 31 |
| alfa | 31 |
| Trial | 31 |
| PA | 31 |
| BP | 31 |
| SC | 30 |
| NAIROS | 30 |
| Medicine | 30 |
| L | 30 |
| GA | 30 |
| European | 29 |
| Evaluation | 29 |
| Ministry | 29 |
| multicentre | 29 |
| seront | 29 |
| Wuhan | 28 |
| Protection | 28 |
| olfactive | 27 |
| Springer | 27 |
| Nature | 27 |
| ISSNHL | 27 |
| II | 27 |
| ClinicalTrials.gov | 27 |
| CT | 27 |
| ABV | 27 |
| Coronavirus | 26 |
| Department | 26 |
| Enoxaparin | 26 |
| ICH | 26 |
| Leukine | 26 |
| March | 26 |
| Organization | 26 |
| Period | 26 |
| dornase | 26 |
| par | 26 |
| Board | 25 |
| July | 25 |
| M. | 25 |
| Society | 25 |
| T | 25 |
| Zealand | 25 |
| committee | 25 |
| ne | 25 |
| MERS | 24 |
| CTU | 24 |
| IL-1 | 24 |
| International | 24 |
| Le | 24 |
| Unit | 24 |
| SUSAR | 24 |
| Yucatan | 24 |
| cas | 24 |
| données | 24 |
| LEUKINE | 23 |
| Ae | 23 |
| Aedes | 23 |
| CRP | 23 |
| Council | 23 |
| HIRUZ | 23 |
| IMP | 23 |
| IQR | 23 |
| HFNC | 23 |
| Norway | 23 |
| SPIRIT | 23 |
| tocilizumab | 23 |
| Southampton | 23 |
| Treatment | 23 |
| budésonide | 23 |
| meta | 23 |
| PEEP | 23 |
| Control | 22 |
| Center | 22 |
| CoV2 | 22 |
| General | 22 |
| ERCP | 22 |
| Note | 22 |
| − | 22 |
| Ketamine | 21 |
| DENV | 21 |
| ITT | 21 |
| IgM | 21 |
| KFSH&RC | 21 |
| CI | 21 |
| NHS | 21 |
| World | 21 |
| après | 21 |
| ® | 21 |
| μg | 21 |
| Questionnaire | 21 |
| Good | 20 |
| Azithromycin | 20 |
| Beijing | 20 |
| Centre | 20 |
| Germany | 20 |
| Ghent | 20 |
| ICF | 20 |
| LIVE@Home | 20 |
| La | 20 |
| Management | 20 |
| NIPPV | 20 |
| PE | 20 |
| Scale | 20 |
| VAS | 20 |
| IgG | 19 |
| AQI | 19 |
| American | 19 |
| Association | 19 |
| Cox | 19 |
| Human | 19 |
| V | 19 |
| June | 19 |
| Primary | 19 |
| REDCap | 19 |
| nez | 19 |
| sans | 19 |
| Merida | 19 |
| EORTC | 18 |
| PK | 18 |
| OVID | 18 |
| Mexico | 18 |
| Madagascar | 18 |
| Appendix | 18 |
| ECG | 18 |
| CoV | 18 |
| Anakinra | 18 |
| Practice | 18 |
| Patients | 18 |
| Une | 18 |
| Registry | 18 |
| SpO2 | 18 |
| US | 18 |
| symptômes | 18 |
| Version | 18 |
| anakinra | 18 |
| https://doi.org/10 | 18 |
| s13063 | 18 |
| signes | 18 |
| SoA | 18 |
| EC | 17 |
| III | 17 |
| IEC | 17 |
| ID | 17 |
| France | 17 |
| CEC | 17 |
| Dementia | 17 |
| DSMB | 17 |
| Criteria | 17 |
| OUTCOMES | 17 |
| Brescia | 17 |
| LDH | 17 |
| COMPARATOR | 17 |
| P | 17 |
| ayant | 17 |
| totalement | 17 |
| min | 17 |
| iloprost | 17 |
| d'une | 17 |
| récupéré | 17 |
| _ | 17 |
| Ward | 17 |
| Review | 17 |
| RM | 17 |
| RASS | 17 |
| Public | 17 |
| Saudi | 16 |
| Berlin | 16 |
| C5 | 16 |
| Chlamydia | 16 |
| ELISA | 16 |
| FDA | 16 |
| Kaplan | 16 |
| M | 16 |
| Meier | 16 |
| October | 16 |
| South | 16 |
| Sciences | 16 |
| USA | 16 |
| Un | 16 |
| Zika | 16 |
| amoxicillin | 16 |
| budesonide | 16 |
| capacités | 16 |
| cours | 16 |
| indésirables | 16 |
| Steering | 16 |
| EDTA | 15 |
| LOS | 15 |
| Fisher | 15 |
| Efficacy | 15 |
| NIH | 15 |
| December | 15 |
| Central | 15 |
| CONSORT | 15 |
| BMI | 15 |
| MBV | 15 |
| September | 15 |
| Norwegian | 15 |
| Regulation | 15 |
| Respiratory | 15 |
| qui | 15 |
| aegypti | 15 |
| ketamine | 15 |
| monitoring | 15 |
| olfactives | 15 |
| PD | 15 |
| FULL | 14 |
| Plan | 14 |
| Number | 14 |
| Mann | 14 |
| Life | 14 |
| GDPR | 14 |
| Foundation | 14 |
| Chronic | 14 |
| EQ-5D-5L | 14 |
| Drug | 14 |
| D | 14 |
| RT | 14 |
| Authority | 14 |
| Acute | 14 |
| Pulmonary | 14 |
| November | 14 |
| Report | 14 |
| Whitney | 14 |
| S. | 14 |
| pas | 14 |
| médicament | 14 |
| mL | 14 |
| hydroxychloroquine | 14 |
| ZIKV | 14 |
| formoterol | 14 |
| WHO | 14 |
| UZ | 14 |
| Syndrome | 14 |
| Specialist | 14 |
| SpO | 14 |
| SF-12 | 14 |
| Guatemala | 13 |
| January | 13 |
| Intervention | 13 |
| Information | 13 |
| Index | 13 |
| IPM | 13 |
| ICS | 13 |
| HCS | 13 |
| 8) | 13 |
| Form | 13 |
| EudraCT | 13 |
| Effect | 13 |
| EACH | 13 |
| CHIKV | 13 |
| August | 13 |
| Organ | 13 |
| NIV | 13 |
| First | 13 |
| PNIF | 13 |
| State | 13 |
| groupe | 13 |
| chez | 13 |
| 13 | |
| Use | 13 |
| Technology | 13 |
| Swissmedic | 13 |
| rééducation | 13 |
| PROTOCOL | 13 |
| Sarilumab | 13 |
| RR | 13 |
| RANDOMISED | 13 |
| RANDOMISATION | 13 |
| Quality | 13 |
| Prevention | 13 |
| SPV | 13 |
| IL-10 | 12 |
| Nutrition | 12 |
| Northern | 12 |
| NPR | 12 |
| JWBY | 12 |
| Italy | 12 |
| Iloprost | 12 |
| Il | 12 |
| IMV | 12 |
| Emory | 12 |
| Helsinki | 12 |
| Failure | 12 |
| England | 12 |
| Darwin | 12 |
| D21 | 12 |
| D11 | 12 |
| CytoSorb | 12 |
| PI | 12 |
| Act | 12 |
| Agency | 12 |
| ODORATEST | 12 |
| PM | 12 |
| Wales | 12 |
| Peking | 12 |
| prednisone | 12 |
| personnes | 12 |
| délai | 12 |
| d'un | 12 |
| contrôle | 12 |
| clavulanic | 12 |
| cette | 12 |
| amélioration | 12 |
| siltuximab | 12 |
| United | 12 |
| States | 12 |
| Standard | 12 |
| Sequential | 12 |
| Science | 12 |
| SAS | 12 |
| SAP | 12 |
| RDT | 12 |
| Strasbourg | 12 |
| H. | 11 |
| EU | 11 |
| Laboratory | 11 |
| Intensive | 11 |
| Hot | 11 |
| ICUs | 11 |
| Institutional | 11 |
| Distress | 11 |
| EN | 11 |
| Bergen | 11 |
| Development | 11 |
| Dans | 11 |
| CPP | 11 |
| Australian | 11 |
| Arabic | 11 |
| Analysis | 11 |
| Acacia | 11 |
| AUC | 11 |
| KCE | 11 |
| FiO | 11 |
| London | 11 |
| gravité | 11 |
| Lung | 11 |
| vous | 11 |
| thromboprophylaxis | 11 |
| présentant | 11 |
| pour | 11 |
| investigateurs | 11 |
| indésirable | 11 |
| il | 11 |
| réalisé | 11 |
| Tritube | 11 |
| Screening | 11 |
| QRI | 11 |
| NaCl | 11 |
| NIHR | 11 |
| Mashhad | 11 |
| MIC | 11 |
| Tocilizumab | 11 |
| Innovation | 10 |
| Fondation | 10 |
| GP | 10 |
| Glasgow | 10 |
| Hydroxychloroquine | 10 |
| Infectious | 10 |
| Max | 10 |
| Interventional | 10 |
| MRC | 10 |
| Mantel | 10 |
| PaO2 | 10 |
| East | 10 |
| FAMHP | 10 |
| Al | 10 |
| Dr. | 10 |
| Denmark | 10 |
| Declaration | 10 |
| DVT | 10 |
| Coordinating | 10 |
| Code | 10 |
| Clinic | 10 |
| Atorvastatin | 10 |
| Principal | 10 |
| Advisory | 10 |
| Adolphe | 10 |
| ACCORD | 10 |
| Pneumonia | 10 |
| Prophylaxis | 10 |
| perte | 10 |
| Wilcoxon | 10 |
| | 10 |
| selon | 10 |
| protocole | 10 |
| prise | 10 |
| Publisher | 10 |
| patients | 10 |
| n'ayant | 10 |
| lavages | 10 |
| l'ANSM | 10 |
| b. | 10 |
| administration | 10 |
| Xa | 10 |
| ciprofloxacin | 10 |
| Wang | 10 |
| SARTRE | 10 |
| QOL | 10 |
| RDS | 10 |
| UADY | 10 |
| Ravulizumab | 10 |
| Rothschild | 10 |
| RIS | 10 |
| SPSS | 10 |
| Siltuximab | 10 |
| Territory | 10 |
| U | 10 |
| Confidential | 9 |
| Hôpital | 9 |
| Hematology | 9 |
| Haenszel | 9 |
| HPA | 9 |
| Gum | 9 |
| Food | 9 |
| EDC | 9 |
| ECMO | 9 |
| Injection | 9 |
| Competent | 9 |
| Chloride | 9 |
| Chi | 9 |
| Case | 9 |
| CAM | 9 |
| CA | 9 |
| C. | 9 |
| AEMPS | 9 |
| ICC | 9 |
| × | 9 |
| Institutes | 9 |
| Statistical | 9 |
| L'investigateur | 9 |
| l'inclusion | 9 |
| drug(s | 9 |
| biobank | 9 |
| atteinte | 9 |
| Ulrik | 9 |
| Supplementary | 9 |
| Summary | 9 |
| patient | 9 |
| Septoplasty | 9 |
| Middle | 9 |
| SOT | 9 |
| PPI | 9 |
| Oxford | 9 |
| Nasal | 9 |
| Monitor | 9 |
| Santé | 9 |
| Diseases | 8 |
| Dose | 8 |
| ENT | 8 |
| Europe | 8 |
| Fudan | 8 |
| GCS | 8 |
| GDS | 8 |
| Huang | 8 |
| GPs | 8 |
| Guidelines | 8 |
| Healthcare | 8 |
| Huashan | 8 |
| Informed | 8 |
| Jens | 8 |
| Master | 8 |
| Danish | 8 |
| De | 8 |
| Barthel | 8 |
| DHI | 8 |
| D. | 8 |
| PTA | 8 |
| ACC | 8 |
| Agreement | 8 |
| America | 8 |
| Arabia | 8 |
| Azienda | 8 |
| BPD | 8 |
| Barcelona | 8 |
| Belgium | 8 |
| Bronchiectasis | 8 |
| CS | 8 |
| Children | 8 |
| Chinese | 8 |
| Chloroquine | 8 |
| Coma | 8 |
| OBJECTIVES | 8 |
| I | 8 |
| Peter | 8 |
| Survey | 8 |
| TRAUMADORNASE | 8 |
| Therapy | 8 |
| USP | 8 |
| Union | 8 |
| Zurich | 8 |
| anti | 8 |
| chaque | 8 |
| en | 8 |
| max | 8 |
| modalités | 8 |
| olfactif | 8 |
| post | 8 |
| steering | 8 |
| suivi | 8 |
| Phase | 8 |
| Switzerland | 8 |
| d'odorat | 8 |
| Stroke | 8 |
| Regional | 8 |
| Si | 8 |
| Pourcentage | 8 |
| Project | 8 |
| traitements | 8 |
| QLQ | 8 |
| RUD | 8 |
| Reference | 8 |
| QY | 8 |
| SD | 8 |
| SNOT-22 | 8 |
| SOFA | 8 |
| STUDY | 8 |
| School | 8 |
| Royal | 8 |
| Score | 8 |
| GOLD | 7 |
| HMI | 7 |
| INR | 7 |
| Hospitalised | 7 |
| Harmonisation | 7 |
| Gentofte | 7 |
| HMC | 7 |
| Government | 7 |
| Jensen | 7 |
| JH | 7 |
| Netherlands | 7 |
| John | 7 |
| MEDI3506 | 7 |
| Medicina | 7 |
| Medicines | 7 |
| Methylprednisolone | 7 |
| NGT | 7 |
| NYHA | 7 |
| Partner | 7 |
| FAS | 7 |
| February | 7 |
| AST | 7 |
| Effectiveness | 7 |
| Directive | 7 |
| -80 | 7 |
| 1mg | 7 |
| ASB | 7 |
| Pharmacy | 7 |
| Argentina | 7 |
| B. | 7 |
| C30 | 7 |
| CDC | 7 |
| CFU | 7 |
| CO | 7 |
| CRCT | 7 |
| Cette | 7 |
| Child | 7 |
| Coagulopathy | 7 |
| Conference | 7 |
| Consent | 7 |
| Cpap | 7 |
| Critical | 7 |
| D90 | 7 |
| Paul | 7 |
| IRM | 7 |
| Physical | 7 |
| mcg | 7 |
| d'observation | 7 |
| effet | 7 |
| expérimental | 7 |
| hyposmies | 7 |
| inflammatoire | 7 |
| jugement | 7 |
| l'article | 7 |
| m2 | 7 |
| mRS | 7 |
| methylprednisolone | 7 |
| control | 7 |
| oVEMP | 7 |
| recherche | 7 |
| résultats | 7 |
| survenue | 7 |
| toute | 7 |
| zilucoplan | 7 |
| β1b | 7 |
| | 7 |
| Proactive | 7 |
| corticoïdes | 7 |
| pH | 7 |
| cahier | 7 |
| Subject | 7 |
| RCTs | 7 |
| cadre | 7 |
| RMs | 7 |
| RSV | 7 |
| Reporting | 7 |
| S | 7 |
| SRM | 7 |
| Scientific | 7 |
| Services | 7 |
| Risk | 7 |
| System | 7 |
| TMG | 7 |
| TNF | 7 |
| Therapeutics | 7 |
| Trust | 7 |
| Unità | 7 |
| acalabrutinib | 7 |
| Y. | 7 |
| GraphPad | 6 |
| Hôpitaux | 6 |
| ISRCTN | 6 |
| IRS | 6 |
| IBW | 6 |
| IB | 6 |
| Hb | 6 |
| High | 6 |
| Head | 6 |
| H1N1 | 6 |
| HR | 6 |
| HIV | 6 |
| Implementation | 6 |
| Impact | 6 |
| NCI | 6 |
| Inc. | 6 |
| Iran | 6 |
| KINERET | 6 |
| KM | 6 |
| MBS | 6 |
| MD | 6 |
| MH | 6 |
| MIRACLE | 6 |
| NF | 6 |
| NOSE | 6 |
| NPS | 6 |
| NS | 6 |
| GI | 6 |
| NT | 6 |
| Grade | 6 |
| Baseline | 6 |
| Functional | 6 |
| Christian | 6 |
| Novel | 6 |
| 2h | 6 |
| APACHE | 6 |
| AR | 6 |
| AS | 6 |
| Adelaide | 6 |
| Administration | 6 |
| Airway | 6 |
| Background | 6 |
| Bushen | 6 |
| CFR | 6 |
| CPCS | 6 |
| Characteristics | 6 |
| Common | 6 |
| Forms | 6 |
| Component | 6 |
| Consensus | 6 |
| Critère | 6 |
| DNase | 6 |
| DP | 6 |
| DR | 6 |
| Division | 6 |
| E. | 6 |
| English | 6 |
| FEV | 6 |
| Fleming | 6 |
| Flow | 6 |
| Force | 6 |
| North | 6 |
| SARs | 6 |
| PIC2 | 6 |
| lavage | 6 |
| b.i.d | 6 |
| bras | 6 |
| catarrhalis | 6 |
| clarithromycin | 6 |
| clinique | 6 |
| comme | 6 |
| heparin | 6 |
| hyperinflammatory | 6 |
| hyposmie | 6 |
| hypoxaemia | 6 |
| intratympanic | 6 |
| itraconazole | 6 |
| l'IRM | 6 |
| lors | 6 |
| Zhou | 6 |
| lymphopenia | 6 |
| mmHg | 6 |
| monocyte | 6 |
| ng | 6 |
| ni | 6 |
| μg/4.5 | 6 |
| soit | 6 |
| sont | 6 |
| synbiotics | 6 |
| ° | 6 |
| évaluer | 6 |
| α | 6 |
| PRO | 6 |
| aux | 6 |
| persistante | 6 |
| Yiqi | 6 |
| Secondary | 6 |
| PS | 6 |
| Wei | 6 |
| PaO | 6 |
| Pain | 6 |
| Poisson | 6 |
| Pradeesh | 6 |
| Publique | 6 |
| Queensland | 6 |
| REC | 6 |
| RedCap | 6 |
| Riyadh | 6 |
| SLI | 6 |
| Sanofi | 6 |
| Physiology | 6 |
| Senegal | 6 |
| TOC | 6 |
| Shanghai | 6 |
| VAP | 6 |
| Units | 6 |
| Thomas | 6 |
| TRIN | 6 |
| Thoracic | 6 |
| Student | 6 |
| Standards | 6 |
| Spain | 6 |
| Sivapalan | 6 |
| Universitaires | 6 |
| Low | 5 |
| Investigators | 5 |
| Lancet | 5 |
| Lactobacillus | 5 |
| Kristiansand | 5 |
| King | 5 |
| MCS | 5 |
| KG | 5 |
| K | 5 |
| J. | 5 |
| Illness | 5 |
| Interna | 5 |
| Infection | 5 |
| Incidence | 5 |
| Immunogenicity | 5 |
| IL6 | 5 |
| IL | 5 |
| ICT | 5 |
| Home | 5 |
| Hampshire | 5 |
| MEDENOX | 5 |
| Gent | 5 |
| MEB | 5 |
| Objectif | 5 |
| MMSE | 5 |
| MOH | 5 |
| Prof. | 5 |
| Procalcitonin | 5 |
| Piacenza | 5 |
| Pharmaceuticals | 5 |
| Pediatric | 5 |
| PCS | 5 |
| PADIS | 5 |
| P(A | 5 |
| Outcomes | 5 |
| Ospedaliero | 5 |
| O2 | 5 |
| Nurse | 5 |
| Newcastle | 5 |
| NCTU | 5 |
| Model | 5 |
| Michael | 5 |
| Mental | 5 |
| Melbourne | 5 |
| MUMS | 5 |
| MS | 5 |
| MRI | 5 |
| French | 5 |
| BMBF | 5 |
| File | 5 |
| Brisbane | 5 |
| Biomedical | 5 |
| Baerum | 5 |
| BACKGROUND | 5 |
| Avez | 5 |
| Auckland | 5 |
| Asthma | 5 |
| Article | 5 |
| Apr | 5 |
| Ageing | 5 |
| Aerogen | 5 |
| Activity | 5 |
| AT | 5 |
| ASH | 5 |
| ASA | 5 |
| ANZCTR | 5 |
| ANCE | 5 |
| AIIMS | 5 |
| ADL | 5 |
| ACE2 | 5 |
| AB | 5 |
| Q | 5 |
| Breast | 5 |
| Burden | 5 |
| Faisal | 5 |
| CD4 | 5 |
| Factor | 5 |
| FCV | 5 |
| Eye | 5 |
| Empowerment | 5 |
| Elizabeth | 5 |
| Education | 5 |
| EIG | 5 |
| E6 | 5 |
| Delirium | 5 |
| DNA | 5 |
| Cov-2 | 5 |
| Controlled | 5 |
| Clinicaltrials.gov | 5 |
| Clexane | 5 |
| Ciprofloxacin | 5 |
| Christchurch | 5 |
| Charlotte | 5 |
| Card | 5 |
| CTC | 5 |
| CSB | 5 |
| CD8 | 5 |
| Proportion | 5 |
| c. | 5 |
| R | 5 |
| multiorgan | 5 |
| ml | 5 |
| lopinavir | 5 |
| leur | 5 |
| l'hyposmie | 5 |
| l'anosmie | 5 |
| l'EIG | 5 |
| kB | 5 |
| instauré | 5 |
| impliquant | 5 |
| gustatives | 5 |
| group | 5 |
| fondaparinux | 5 |
| est | 5 |
| entre | 5 |
| dès | 5 |
| droit | 5 |
| doc_id | 5 |
| disease(s | 5 |
| date | 5 |
| d'infection | 5 |
| d'auto | 5 |
| mois | 5 |
| nasale | 5 |
| centre | 5 |
| nebulised | 5 |
| RNA | 5 |
| | 5 |
| ≥2 | 5 |
| κB | 5 |
| évaluation | 5 |
| © | 5 |
| tout | 5 |
| sévérité | 5 |
| sur | 5 |
| statistique | 5 |
| réalisée | 5 |
| ritonavir | 5 |
| requirement(s | 5 |
| randomisation | 5 |
| questionnaire | 5 |
| qPCR | 5 |
| présence | 5 |
| première | 5 |
| persistance | 5 |
| niveau | 5 |
| neurologique | 5 |
| d'Urgenza | 5 |
| remdesivir | 5 |
| bronchiolitis | 5 |
| Sterimar | 5 |
| Software | 5 |
| SoC | 5 |
| Self | 5 |
| Section | 5 |
| Scotland | 5 |
| SYLVANT | 5 |
| STATA | 5 |
| SSY | 5 |
| SF-36 | 5 |
| SARILUMAB | 5 |
| SAR | 5 |
| Roche | 5 |
| Robert | 5 |
| Rivaroxaban | 5 |
| Recruitment | 5 |
| Reaction | 5 |
| Rankin | 5 |
| Randomization | 5 |
| RSS | 5 |
| bivalirudin | 5 |
| ROACTEMRA | 5 |
| Spray | 5 |
| Requirements | 5 |
| Streptococcus | 5 |
| Universitaria | 5 |
| associés | 5 |
| atorvastatin | 5 |
| Stress | 5 |
| Yang | 5 |
| YH | 5 |
| Welfare | 5 |
| Ventilator | 5 |
| Vanderbilt | 5 |
| VNG | 5 |
| Utilization | 5 |
| Wilson | 5 |
| UW | 5 |
| Townsville | 5 |
| Task | 5 |
| UI | 5 |
| TSC | 5 |
| Test | 5 |
| ThIlo | 5 |
| Tuebingen | 5 |
| UF | 5 |
| Team | 5 |
| Indigenous | 4 |
| Internal | 4 |
| India | 4 |
| Inhixa | 4 |
| Initiative | 4 |
| Injury | 4 |
| Ill | 4 |
| Item | 4 |
| Inventory | 4 |
| Ireland | 4 |
| J | 4 |
| J30 | 4 |
| JB | 4 |
| IVRS | 4 |
| James | 4 |
| Je | 4 |
| Identifier | 4 |
| HMGB1 | 4 |
| ISTH | 4 |
| IP-10 | 4 |
| GINA | 4 |
| Josefin | 4 |
| GRV | 4 |
| German | 4 |
| Guideline | 4 |
| HDAC | 4 |
| HGH | 4 |
| HLA | 4 |
| HRQoL | 4 |
| Heart | 4 |
| Herlev | 4 |
| Hunter | 4 |
| IBM | 4 |
| IFN | 4 |
| IL-8 | 4 |
| Jia | 4 |
| Myocardial | 4 |
| Joseph | 4 |
| Kevzara | 4 |
| Mortality | 4 |
| Multicentre | 4 |
| N. | 4 |
| NCT02917551 | 4 |
| NHMRC | 4 |
| NIHSS | 4 |
| NUTRIC | 4 |
| Network | 4 |
| Neutrophil | 4 |
| O'Brien | 4 |
| OSA | 4 |
| Objectives | 4 |
| Operativa | 4 |
| Organisation | 4 |
| FiO2 | 4 |
| Mohamed | 4 |
| Modena | 4 |
| Mini | 4 |
| Latin | 4 |
| Kingdom | 4 |
| Kong | 4 |
| L. | 4 |
| LABA | 4 |
| LEU | 4 |
| LMST | 4 |
| Law | 4 |
| Meyer | 4 |
| Lisa | 4 |
| Liu | 4 |
| LoMV | 4 |
| MRC-05 | 4 |
| Manual | 4 |
| Marie | 4 |
| Figure | 4 |
| Annexe | 4 |
| Federal | 4 |
| Actellic | 4 |
| Agitation | 4 |
| Alan | 4 |
| Alexander | 4 |
| Ali | 4 |
| Allergy | 4 |
| Alzheimer | 4 |
| Anti | 4 |
| Applied | 4 |
| Asia | 4 |
| Au | 4 |
| Aucune | 4 |
| BAL | 4 |
| Bacteremia | 4 |
| Behavior | 4 |
| Bi | 4 |
| Age | 4 |
| AZ | 4 |
| Exclusion | 4 |
| ATTAINMENT | 4 |
| PRECIOUS | 4 |
| -Age | 4 |
| -Autres | 4 |
| -Grade | 4 |
| -The | 4 |
| 300CS | 4 |
| 30min | 4 |
| 5d | 4 |
| ABG | 4 |
| ABGs | 4 |
| ADA | 4 |
| AG | 4 |
| AIM | 4 |
| ALRI | 4 |
| ATIII | 4 |
| Bronchiolitis | 4 |
| CCCTG | 4 |
| CENAPRECE | 4 |
| CF | 4 |
| Definition | 4 |
| Diagnosis | 4 |
| Dipartimento | 4 |
| Dornase | 4 |
| Dr | 4 |
| E9 | 4 |
| EQ | 4 |
| Early | 4 |
| Eklöf | 4 |
| Environmental | 4 |
| Epidemiology | 4 |
| Ethical | 4 |
| EuroQol | 4 |
| Evaluer | 4 |
| Evone | 4 |
| Danone | 4 |
| Daniel | 4 |
| Daily | 4 |
| Chiew | 4 |
| CPK | 4 |
| CPL | 4 |
| CVD | 4 |
| Canberra | 4 |
| Ce | 4 |
| Checklist | 4 |
| CleanWeb | 4 |
| D7 | 4 |
| ClinicalStudies.gov | 4 |
| Cochran | 4 |
| Committees | 4 |
| Complications | 4 |
| Consolidated | 4 |
| Copenhagen | 4 |
| Oslo | 4 |
| PBS | 4 |
| rapport | 4 |
| drug | 4 |
| fièvre | 4 |
| gentamicin | 4 |
| humaine | 4 |
| initiale | 4 |
| interventionnelle | 4 |
| jusqu'à | 4 |
| k0 | 4 |
| l'efficacité | 4 |
| l'essai | 4 |
| l'intérêt | 4 |
| l'investigateur | 4 |
| lien | 4 |
| lié | 4 |
| mais | 4 |
| mm | 4 |
| eCRFs | 4 |
| devront | 4 |
| ainsi | 4 |
| dechallenge | 4 |
| association | 4 |
| aucune | 4 |
| author(s | 4 |
| autres | 4 |
| ces | 4 |
| cfr | 4 |
| chemoattractant | 4 |
| chi | 4 |
| ci | 4 |
| cliniques | 4 |
| complémentaires | 4 |
| compétente | 4 |
| d'hospitalisation | 4 |
| d'étude | 4 |
| d'événements | 4 |
| ms | 4 |
| n'est | 4 |
| non | 4 |
| notamment | 4 |
| soumise | 4 |
| specialized | 4 |
| square | 4 |
| total | 4 |
| traité | 4 |
| transmis | 4 |
| type | 4 |
| virale | 4 |
| voriconazole | 4 |
| écrit | 4 |
| évaluée | 4 |
| évènement | 4 |
| ≥75 | 4 |
| | 4 |
| PRISM | 4 |
| son | 4 |
| sa | 4 |
| s'agit | 4 |
| pourra | 4 |
| nous | 4 |
| olfactifs | 4 |
| ont | 4 |
| pCO | 4 |
| personne | 4 |
| posaconazole | 4 |
| predose | 4 |
| respiratoires | 4 |
| premiers | 4 |
| produit | 4 |
| prostacyclin | 4 |
| protection | 4 |
| prévue | 4 |
| qualité | 4 |
| antiXa | 4 |
| investigateur | 4 |
| Zheng | 4 |
| RDW | 4 |
| RSI | 4 |
| Red | 4 |
| Register | 4 |
| Reliability | 4 |
| S.A.S. | 4 |
| S1 | 4 |
| SAA | 4 |
| SABA | 4 |
| SE | 4 |
| SS | 4 |
| SSNHL | 4 |
| STS | 4 |
| Salud | 4 |
| San | 4 |
| Sarah | 4 |
| RGPD | 4 |
| RAC | 4 |
| Scutellaria | 4 |
| RA | 4 |
| PUMP | 4 |
| PVS | 4 |
| PWD | 4 |
| Pathway | 4 |
| Performance | 4 |
| Pfizer | 4 |
| Pharmaceutical | 4 |
| Practices | 4 |
| Prior | 4 |
| Prism | 4 |
| Zhao | 4 |
| QT | 4 |
| Qatar | 4 |
| Qin | 4 |
| Queen | 4 |
| Scheme | 4 |
| Pugh | 4 |
| Security | 4 |
| V1 | 4 |
| Thromboembolic | 4 |
| Thrombosis | 4 |
| Tropical | 4 |
| Tübingen | 4 |
| UC | 4 |
| USZ | 4 |
| Utrecht | 4 |
| VEK | 4 |
| Telemedicine | 4 |
| VFD | 4 |
| Ventilation | 4 |
| West | 4 |
| Windows | 4 |
| Wu | 4 |
| XY | 4 |
| Service | 4 |
| Thrombocytopenia | 4 |
| VILI | 4 |
| Technologies | 4 |
| Sustainability | 4 |
| Shao | 4 |
| Short | 4 |
| Sleep | 4 |
| Stata | 4 |
| Stefan | 4 |
| Studies | 4 |
| Sophie | 4 |
| Swiss | 4 |
| Sørensen | 4 |
| TE | 4 |
| Technical | 4 |
| TLRs | 4 |
| TTCI | 4 |
| Immunoglobulins | 3 |
| Informant | 3 |
| Influenza | 3 |
| Infarction | 3 |
| Independence | 3 |
| Ian | 3 |
| IgA | 3 |
| INTERVENTION | 3 |
| ISS | 3 |
| IRR | 3 |
| Interactive | 3 |
| IQCODE | 3 |
| Innsbruck | 3 |
| J60 | 3 |
| Interleukin-6 | 3 |
| Interventions | 3 |
| Iquitos | 3 |
| Italian | 3 |
| Japan | 3 |
| J8 | 3 |
| JMG | 3 |
| JP | 3 |
| JUJ | 3 |
| Jana | 3 |
| IL-4 | 3 |
| Jeffreys | 3 |
| IL10 | 3 |
| H5N1 | 3 |
| IL-2 | 3 |
| HEPA | 3 |
| Journal | 3 |
| GCSE | 3 |
| GEE | 3 |
| GLM | 3 |
| Gault | 3 |
| Giessen | 3 |
| Granollers | 3 |
| Grant | 3 |
| Groetzinger | 3 |
| Guide | 3 |
| HEM-7121 | 3 |
| HRA | 3 |
| IDACI | 3 |
| HRC | 3 |
| HREC | 3 |
| HRT | 3 |
| HS | 3 |
| HSP70 | 3 |
| HTA | 3 |
| Haemophilus | 3 |
| Harmonization | 3 |
| Haryana | 3 |
| Hospitalized | 3 |
| IAC | 3 |
| Jhajjar | 3 |
| ACP | 3 |
| KWT | 3 |
| Karnofsky | 3 |
| Martin | 3 |
| Mary | 3 |
| Medicamentos | 3 |
| Medicare | 3 |
| Menzies | 3 |
| Metro | 3 |
| MoCA | 3 |
| Mohammad | 3 |
| Mohammed | 3 |
| Mometasone | 3 |
| Monte | 3 |
| Morris | 3 |
| Mustafa | 3 |
| NC | 3 |
| NCPAP | 3 |
| NCT04043364 | 3 |
| NE | 3 |
| NETs | 3 |
| NOMID | 3 |
| Neck | 3 |
| Neonatology | 3 |
| Nov | 3 |
| Nursing | 3 |
| OBF | 3 |
| Frederick | 3 |
| Marnik | 3 |
| Mark | 3 |
| Marc | 3 |
| Limited | 3 |
| Keith | 3 |
| L'analyse | 3 |
| LC | 3 |
| LIB | 3 |
| Lan | 3 |
| Lance | 3 |
| Lariboisière | 3 |
| Laura | 3 |
| Layer | 3 |
| Library | 3 |
| Lifecourse | 3 |
| Locale | 3 |
| Mackay | 3 |
| Lopinavir | 3 |
| Ltd | 3 |
| Ltd. | 3 |
| M3 | 3 |
| MA | 3 |
| MAP | 3 |
| MAR | 3 |
| MB | 3 |
| MMRM | 3 |
| MOF | 3 |
| MR | 3 |
| G | 3 |
| Benefit | 3 |
| Fred | 3 |
| Bivalirudin | 3 |
| Area | 3 |
| Aspirin | 3 |
| Assurance | 3 |
| Autonomous | 3 |
| BI | 3 |
| BNP | 3 |
| Bart | 3 |
| Behaviour | 3 |
| Omron | 3 |
| Biobank | 3 |
| Biotechnology | 3 |
| Blood | 3 |
| Antibiotic | 3 |
| British | 3 |
| Brochure | 3 |
| Bubo | 3 |
| Budesonide | 3 |
| C3 | 3 |
| CACE | 3 |
| CHES | 3 |
| CIOMS | 3 |
| COSMOS | 3 |
| COVID19 | 3 |
| CP | 3 |
| Anticoagulation | 3 |
| Anthony | 3 |
| CURE | 3 |
| ANCOVA | 3 |
| -Traitement | 3 |
| -first | 3 |
| 05th | 3 |
| A. | 3 |
| ABC | 3 |
| ACE-2 | 3 |
| AHA | 3 |
| ALI | 3 |
| ALT | 3 |
| ALXN1210-COV-305 | 3 |
| AMI | 3 |
| ANOVA | 3 |
| Anne | 3 |
| ANSM | 3 |
| Abdullah | 3 |
| Access | 3 |
| Alexandra | 3 |
| Alireza | 3 |
| Amin | 3 |
| Anaesthesia | 3 |
| Andrew | 3 |
| Anesthesiology | 3 |
| Anita | 3 |
| Ann | 3 |
| CSLD | 3 |
| CV | 3 |
| Ficam | 3 |
| Elisabeth | 3 |
| DC | 3 |
| DS | 3 |
| Delhi | 3 |
| Depression | 3 |
| Design | 3 |
| Diagnostics | 3 |
| Diego | 3 |
| Director | 3 |
| Dolquine | 3 |
| Drs | 3 |
| E | 3 |
| Endpoints | 3 |
| D5 | 3 |
| Erik | 3 |
| Escherichia | 3 |
| Excel | 3 |
| Experience | 3 |
| FAGG | 3 |
| FAST | 3 |
| FFQ | 3 |
| FRC | 3 |
| FRNT50 | 3 |
| Faculty | 3 |
| FeNO | 3 |
| DAOH14 | 3 |
| D28 | 3 |
| CVS | 3 |
| Class | 3 |
| CYP3A4 | 3 |
| Cardiology | 3 |
| Cardiovascular | 3 |
| Carlo | 3 |
| Cary | 3 |
| Cedex | 3 |
| Centres | 3 |
| Chang | 3 |
| Change | 3 |
| Chase | 3 |
| Chu | 3 |
| Clinique | 3 |
| Curriculum | 3 |
| Co | 3 |
| Co. | 3 |
| Cockcroft | 3 |
| Cognitive | 3 |
| College | 3 |
| Combination | 3 |
| Company | 3 |
| Contraindications | 3 |
| Corporation | 3 |
| Critica | 3 |
| Cross | 3 |
| Observation | 3 |
| Infusion | 3 |
| Oncology | 3 |
| matin | 3 |
| green | 3 |
| générale | 3 |
| hs | 3 |
| human | 3 |
| informera | 3 |
| intErferon | 3 |
| interrompre | 3 |
| isolée | 3 |
| jours | 3 |
| ketoconazole | 3 |
| key | 3 |
| kétoconazole | 3 |
| l'AMM | 3 |
| l'apparition | 3 |
| l'appel | 3 |
| l'arrêt | 3 |
| l'autorité | 3 |
| l'e | 3 |
| l'effet | 3 |
| l'infection | 3 |
| l'objet | 3 |
| l'odorat | 3 |
| littérature | 3 |
| m(2 | 3 |
| m1 | 3 |
| grave | 3 |
| fente | 3 |
| examens | 3 |
| cytomegalovirus | 3 |
| clinicaltrials.gov | 3 |
| cmH | 3 |
| comité | 3 |
| compte | 3 |
| confirmée | 3 |
| conséquences | 3 |
| contre | 3 |
| contrôlé | 3 |
| corticoïde | 3 |
| critère | 3 |
| critères | 3 |
| d'EIG | 3 |
| essais | 3 |
| d'ORL | 3 |
| d'environ | 3 |
| d'information | 3 |
| del | 3 |
| department | 3 |
| devra | 3 |
| di | 3 |
| dose | 3 |
| durée | 3 |
| déconseillé | 3 |
| essai | 3 |
| manquantes | 3 |
| meningitidis | 3 |
| cet | 3 |
| metapneumovirus | 3 |
| sRAGE | 3 |
| scan | 3 |
| si | 3 |
| significatif | 3 |
| spray | 3 |
| t4-t5 | 3 |
| tReated | 3 |
| test | 3 |
| therapy | 3 |
| thoracique | 3 |
| télithromycine | 3 |
| vHIT | 3 |
| virales | 3 |
| voie | 3 |
| ward | 3 |
| yellow | 3 |
| échéant | 3 |
| étiquetage | 3 |
| évènements | 3 |
| événements | 3 |
| β | 3 |
| γ | 3 |
| ≥ | 3 |
| ▪ | 3 |
| Optimal | 3 |
| sHLH | 3 |
| sC5b-9 | 3 |
| revus | 3 |
| od | 3 |
| modifié | 3 |
| mon | 3 |
| moyenne | 3 |
| myogenic | 3 |
| médicalement | 3 |
| méthodologiste | 3 |
| nHL | 3 |
| nasales | 3 |
| nature | 3 |
| notés | 3 |
| nouveau | 3 |
| oui | 3 |
| red | 3 |
| parainfluenza | 3 |
| parait | 3 |
| pharmacie | 3 |
| physiologique | 3 |
| piperacillin | 3 |
| place | 3 |
| prendra | 3 |
| pronostic | 3 |
| publications | 3 |
| qD | 3 |
| recueillies | 3 |
| clarithromycine | 3 |
| odeurs | 3 |
| centres | 3 |
| Sant | 3 |
| R2 | 3 |
| RANDOMIZATION | 3 |
| RE | 3 |
| Random | 3 |
| Randomized | 3 |
| Rebecca | 3 |
| Recherche | 3 |
| Recommendations | 3 |
| Record | 3 |
| Registration | 3 |
| Regulatory | 3 |
| Relative | 3 |
| Requirement | 3 |
| Resource | 3 |
| Response | 3 |
| Resuscitation | 3 |
| Richard | 3 |
| Robust | 3 |
| S2 | 3 |
| S3 | 3 |
| S4 | 3 |
| S5 | 3 |
| S6 | 3 |
| SH | 3 |
| ST | 3 |
| Pseudomonas | 3 |
| Programme | 3 |
| Program | 3 |
| Paracetamol | 3 |
| Ordonnance | 3 |
| ce | 3 |
| Outcome | 3 |
| PIC | 3 |
| PIC1 | 3 |
| PO | 3 |
| PPS | 3 |
| PROMMTT | 3 |
| Package | 3 |
| Pan | 3 |
| Panama | 3 |
| Participant | 3 |
| Professor | 3 |
| Pau | 3 |
| Paykel | 3 |
| Perth | 3 |
| Peru | 3 |
| Picker | 3 |
| Placebo | 3 |
| Plató | 3 |
| Pour | 3 |
| Pressure | 3 |
| Preventive | 3 |
| Product | 3 |
| Sanitaria | 3 |
| Pregnancy | 3 |
| Sargramostim | 3 |
| VLBWI | 3 |
| Vincent | 3 |
| Viral | 3 |
| Vuylsteke | 3 |
| WBC | 3 |
| Weaning | 3 |
| XX | 3 |
| Xia | 3 |
| Year | 3 |
| Young | 3 |
| Youth | 3 |
| Zihui | 3 |
| a)O2 | 3 |
| airways | 3 |
| ampicillin | 3 |
| arthroplasty | 3 |
| associée | 3 |
| avant | 3 |
| avec | 3 |
| base | 3 |
| bemcentinib | 3 |
| bilatérale | 3 |
| bulbe | 3 |
| Schedule | 3 |
| cVEMP | 3 |
| caf-1 | 3 |
| Van | 3 |
| alanine | 3 |
| VES | 3 |
| Sweden | 3 |
| Shaw | 3 |
| VEMP | 3 |
| Site | 3 |
| SmPC | 3 |
| Social | 3 |
| Soft | 3 |
| Staphylococcus | 3 |
| Statement | 3 |
| Stæhr | 3 |
| Surgery | 3 |
| Staging | 3 |
| Shapiro | 3 |
| Thromboprophylaxis | 3 |
| U.S. | 3 |
| UFH | 3 |
| TF | 3 |
| Tse | 3 |
| Sepsis | 3 |
| TnI | 3 |
| Therapeutic | 3 |
| Tests | 3 |
| Tang | 3 |
| ITN | 2 |
| Immunomodulatory | 2 |
| ITTI | 2 |
| IVIg | 2 |
| ISF | 2 |
| IRT | 2 |
| IgE | 2 |
| Insuffizienz | 2 |
| Inclusion | 2 |
| Income | 2 |
| Independent | 2 |
| Insecticide | 2 |
| IRCT20200405046958N1 | 2 |
| Inspection | 2 |
| Instruments | 2 |
| Ingi | 2 |
| IL-33 | 2 |
| IRCT | 2 |
| IR | 2 |
| H₀ | 2 |
| Hypoxaemia | 2 |
| Int | 2 |
| Hypoglycaemia | 2 |
| IC | 2 |
| IDT | 2 |
| IIa | 2 |
| IL-2R | 2 |
| IL-7 | 2 |
| IL1 | 2 |
| IL8 | 2 |
| IMA | 2 |
| IMASOY | 2 |
| IMM | 2 |
| IPD | 2 |
| Insufflation | 2 |
| Junjun | 2 |
| Interleukin-1 | 2 |
| Ira | 2 |
| Jose | 2 |
| Jozefien | 2 |
| Julius | 2 |
| Jung | 2 |
| Justus | 2 |
| K+ | 2 |
| KA | 2 |
| KGH | 2 |
| KJR | 2 |
| KL | 2 |
| Karel | 2 |
| Karls | 2 |
| Hypertension | 2 |
| Kcal | 2 |
| Kathryn | 2 |
| Joren | 2 |
| Jon | 2 |
| Johnson | 2 |
| JC | 2 |
| Isabelle | 2 |
| Isfahan | 2 |
| Isles | 2 |
| J-1 | 2 |
| J70 | 2 |
| JAMA | 2 |
| JL | 2 |
| Joanne | 2 |
| Jacobsen | 2 |
| Jaeger | 2 |
| Jenkins | 2 |
| Jennifer | 2 |
| Jiang | 2 |
| Jingcheng | 2 |
| Hypertensive | 2 |
| GW | 2 |
| Hygiene | 2 |
| Hutchinson | 2 |
| Gabrielle | 2 |
| Game | 2 |
| Geneva | 2 |
| Geoff | 2 |
| Geoffrey | 2 |
| Gesellschaft | 2 |
| Gilead | 2 |
| Glostrup | 2 |
| Glucocorticoids | 2 |
| Gralinski | 2 |
| Gram | 2 |
| Graphs | 2 |
| Greece | 2 |
| Grimwood | 2 |
| Groupe | 2 |
| GN | 2 |
| GLMM | 2 |
| GG | 2 |
| Follow | 2 |
| Fait | 2 |
| Khartoum | 2 |
| Fernández | 2 |
| Filip | 2 |
| Flinders | 2 |
| Flyer | 2 |
| Foreground | 2 |
| GENEActiv | 2 |
| Forum | 2 |
| Fowler | 2 |
| Framework | 2 |
| Freeman | 2 |
| Friday | 2 |
| G. | 2 |
| Guangfa | 2 |
| Guo | 2 |
| Guy | 2 |
| Hg | 2 |
| Haraldsplass | 2 |
| Healthy | 2 |
| Helena | 2 |
| Hemostasis | 2 |
| Hepatitis | 2 |
| Her2 | 2 |
| Hierro | 2 |
| Hanson | 2 |
| Hochberg | 2 |
| Hospitalier | 2 |
| Hospitalisation | 2 |
| Hu | 2 |
| Hungary | 2 |
| Hussein | 2 |
| Harald | 2 |
| Hamilton | 2 |
| Général | 2 |
| HLH | 2 |
| H | 2 |
| H3 | 2 |
| HCG | 2 |
| HCO3 | 2 |
| HCPIA | 2 |
| HD | 2 |
| HMGH | 2 |
| Hamad | 2 |
| HW | 2 |
| Habituellement | 2 |
| Haematuria | 2 |
| Haemoptysis | 2 |
| Hall | 2 |
| Halle | 2 |
| Khadem | 2 |
| Nonpharmacologic | 2 |
| Kilwinning | 2 |
| Models | 2 |
| NHANES | 2 |
| NIAID | 2 |
| NK | 2 |
| NNT | 2 |
| NR3 | 2 |
| NSTEMI | 2 |
| NY | 2 |
| NYGH | 2 |
| Naseptin | 2 |
| Natalie | 2 |
| Nathalie | 2 |
| Nationale | 2 |
| Native | 2 |
| Nebulizing | 2 |
| Neisseria | 2 |
| NETosis | 2 |
| NCT04343521 | 2 |
| NCT04322396 | 2 |
| Myopathy | 2 |
| Monday | 2 |
| Monika | 2 |
| Moraxella | 2 |
| Muenster | 2 |
| Municipal | 2 |
| Myeloid | 2 |
| Médicament | 2 |
| NCT04075006 | 2 |
| Même | 2 |
| Møller | 2 |
| Münster | 2 |
| NAT | 2 |
| NCT03504124 | 2 |
| NCT03974867 | 2 |
| Networking | 2 |
| Neuropsychiatric | 2 |
| Non | 2 |
| PF | 2 |
| PAIS | 2 |
| PARI | 2 |
| PBMC | 2 |
| PCT | 2 |
| PCWP | 2 |
| PES | 2 |
| PG-0216 | 2 |
| Otometrics | 2 |
| PH | 2 |
| PHRCI-2017-S09 | 2 |
| PMA | 2 |
| PP | 2 |
| PPE | 2 |
| FVC | 2 |
| P. | 2 |
| Otolaryngol | 2 |
| Nordisk | 2 |
| Nurses | 2 |
| Norms | 2 |
| Nottingham | 2 |
| Nous | 2 |
| Novo | 2 |
| Nucleic | 2 |
| Numbers | 2 |
| O. | 2 |
| Oscar | 2 |
| OBI | 2 |
| OR | 2 |
| ORL | 2 |
| Objective | 2 |
| Open | 2 |
| Operations | 2 |
| Mohsen | 2 |
| Mobilization | 2 |
| Knop | 2 |
| MoPH | 2 |
| Laursen | 2 |
| Lawrence | 2 |
| Leeuw | 2 |
| Length | 2 |
| Lesley | 2 |
| Leukemia | 2 |
| Level | 2 |
| Ley | 2 |
| Li | 2 |
| Libeer | 2 |
| Liebig | 2 |
| Lingwen | 2 |
| Little | 2 |
| Liver | 2 |
| Living | 2 |
| Lars | 2 |
| Lambrecht | 2 |
| Ladder | 2 |
| LDUH | 2 |
| Krag | 2 |
| Kufstein | 2 |
| L'objectif | 2 |
| L'étude | 2 |
| L1121 | 2 |
| LB | 2 |
| LFT | 2 |
| Lactocare | 2 |
| LM | 2 |
| LMVPA | 2 |
| LMW | 2 |
| LSG | 2 |
| LSLV | 2 |
| Lab | 2 |
| Local | 2 |
| Log | 2 |
| Login | 2 |
| Markus | 2 |
| Maintenance | 2 |
| Majid | 2 |
| Mansfield | 2 |
| Manufacturing | 2 |
| Marcus | 2 |
| Markov | 2 |
| McCallum | 2 |
| MYD88 | 2 |
| Mean | 2 |
| MedCalc | 2 |
| Methodological | 2 |
| Methods | 2 |
| Microsoft | 2 |
| Mo | 2 |
| Maes | 2 |
| MOBID | 2 |
| Long | 2 |
| M1 | 2 |
| Longini | 2 |
| Lorsque | 2 |
| Lucia | 2 |
| Luminex | 2 |
| Lundgren | 2 |
| Lv | 2 |
| MAGELLAN | 2 |
| MO | 2 |
| MARINER | 2 |
| MCID | 2 |
| MCS-12 | 2 |
| MDC | 2 |
| MM | 2 |
| MN | 2 |
| Fahrenheit | 2 |
| PREvention | 2 |
| FIO | 2 |
| Auditing | 2 |
| Bemcentinib | 2 |
| Benefits | 2 |
| Benjamin | 2 |
| Bernard | 2 |
| Bernhard | 2 |
| Besançon | 2 |
| Bettina | 2 |
| Biering | 2 |
| Binomial | 2 |
| Biodisk | 2 |
| Biomarker | 2 |
| Biomarkers | 2 |
| Boehringer | 2 |
| Bollé | 2 |
| Bonferroni | 2 |
| Belgian | 2 |
| Behavioural | 2 |
| Bayesian | 2 |
| BEST-2 | 2 |
| Australians | 2 |
| Authorities | 2 |
| Autonomy | 2 |
| Avendaño | 2 |
| BB | 2 |
| BEST | 2 |
| BH | 2 |
| Bayer | 2 |
| BSH | 2 |
| BTK | 2 |
| Bandura | 2 |
| Baojun | 2 |
| Basel | 2 |
| Bastiaan | 2 |
| Booster | 2 |
| Bosteels | 2 |
| Bristol | 2 |
| CSC | 2 |
| CNIL | 2 |
| CNS | 2 |
| COP | 2 |
| COV2 | 2 |
| CPMP | 2 |
| CRO | 2 |
| CTRN12619000397112 | 2 |
| CM | 2 |
| CZ | 2 |
| Cagliari | 2 |
| Cairns | 2 |
| Campus | 2 |
| Canadian | 2 |
| Candidate | 2 |
| CMV | 2 |
| CLSI | 2 |
| Browatzki | 2 |
| C-8 | 2 |
| Brussels | 2 |
| Bubonic | 2 |
| Budésonide | 2 |
| Butyrate | 2 |
| Bénédicte | 2 |
| Bødtger | 2 |
| C5a | 2 |
| CKD | 2 |
| C5aR | 2 |
| C5b-9 | 2 |
| CC | 2 |
| CHE | 2 |
| CHU | 2 |
| CHU9D | 2 |
| Aug. | 2 |
| Audit | 2 |
| Capetillo | 2 |
| Attribution | 2 |
| 500mg | 2 |
| 6-point | 2 |
| 8mg | 2 |
| AC | 2 |
| ACCORD-2 | 2 |
| ACTRN12614001069640 | 2 |
| AEL | 2 |
| AIDS | 2 |
| ANC | 2 |
| ANTI | 2 |
| AP | 2 |
| APA | 2 |
| APTT | 2 |
| ASR | 2 |
| ATS | 2 |
| 3D | 2 |
| 30/≥30 | 2 |
| 1mg/2mL | 2 |
| -Hyposmie | 2 |
| (= | 2 |
| ): | 2 |
| -10 | 2 |
| -8 | 2 |
| -Absence | 2 |
| -Consentement | 2 |
| -Les | 2 |
| 1297·6 | 2 |
| -Male | 2 |
| -Patient | 2 |
| -Pregnancy | 2 |
| -Stratified | 2 |
| -Trouble | 2 |
| 1-min | 2 |
| AW | 2 |
| AWMF | 2 |
| Academy | 2 |
| Angiotensin | 2 |
| Ana | 2 |
| Analgo | 2 |
| Anatomical | 2 |
| Anderson | 2 |
| Andrea | 2 |
| Anesthesiologists | 2 |
| Anja | 2 |
| Ambassadors | 2 |
| Antonio | 2 |
| Application | 2 |
| Arabi | 2 |
| Armonk | 2 |
| Associations | 2 |
| AstraZeneca | 2 |
| Amy | 2 |
| Alveolar | 2 |
| Achaia | 2 |
| Afin | 2 |
| Action | 2 |
| Activities | 2 |
| Adaptive | 2 |
| Adoption | 2 |
| Adults | 2 |
| Aeroneb | 2 |
| Agence | 2 |
| Alison | 2 |
| Agencia | 2 |
| Ahmed | 2 |
| Air | 2 |
| Alain | 2 |
| Albumin | 2 |
| Aliquots | 2 |
| Cantril | 2 |
| Cardiac | 2 |
| FEV1 | 2 |
| David | 2 |
| Disability | 2 |
| Docherty | 2 |
| Dominique | 2 |
| Dong | 2 |
| Données | 2 |
| Doses | 2 |
| Drugs | 2 |
| Du | 2 |
| Dysbiosis | 2 |
| Dyssynchrony | 2 |
| Dès | 2 |
| EMINENT | 2 |
| EOS | 2 |
| EPI | 2 |
| EQ-5D | 2 |
| Direction | 2 |
| Diptera | 2 |
| Dijon | 2 |
| Decuypere | 2 |
| Deaconess | 2 |
| Dean | 2 |
| Deborah | 2 |
| Dec | 2 |
| Declercq | 2 |
| Decline | 2 |
| Defined | 2 |
| Dignity | 2 |
| Delporte | 2 |
| Delta | 2 |
| Demeyere | 2 |
| Des | 2 |
| Description | 2 |
| Dexmedetomidine | 2 |
| ES | 2 |
| ESO | 2 |
| ESPEN | 2 |
| Eva | 2 |
| Eric | 2 |
| Erkrankungen | 2 |
| Española | 2 |
| Essai | 2 |
| Est | 2 |
| Estonia | 2 |
| Examination | 2 |
| Emergenza | 2 |
| Exchange | 2 |
| Executive | 2 |
| Expert | 2 |
| Extended | 2 |
| F-46 | 2 |
| F1 | 2 |
| Endpoint | 2 |
| Embolism | 2 |
| ET | 2 |
| Effet | 2 |
| ETCO | 2 |
| EUDRACT | 2 |
| EUSAPHARMA | 2 |
| Eberhard | 2 |
| Editors | 2 |
| Effective | 2 |
| Ehrhardt | 2 |
| Elsaid | 2 |
| Elderly | 2 |
| Elders | 2 |
| Electronic | 2 |
| Elena | 2 |
| Elle | 2 |
| Elles | 2 |
| DeMets | 2 |
| Daval | 2 |
| Castelman | 2 |
| Database | 2 |
| Chris | 2 |
| Citrullinated | 2 |
| Cl | 2 |
| Clare | 2 |
| Classification | 2 |
| Clement | 2 |
| Clinfile | 2 |
| ClinicalTrials.org | 2 |
| Clinics | 2 |
| Clive | 2 |
| Clínic | 2 |
| CoV-19 | 2 |
| Cohen | 2 |
| Collaborative | 2 |
| Collection | 2 |
| Chicago | 2 |
| Chez | 2 |
| Chemical | 2 |
| Centrifugation | 2 |
| Category | 2 |
| Catherine | 2 |
| Cayman | 2 |
| Cedric | 2 |
| Celsius | 2 |
| Cenduit | 2 |
| Cet | 2 |
| Charter | 2 |
| Chair | 2 |
| Chancellor | 2 |
| Chaque | 2 |
| Charité | 2 |
| Charles | 2 |
| Chart | 2 |
| Commission | 2 |
| Committee(s | 2 |
| Community | 2 |
| D6 | 2 |
| Culicidae | 2 |
| D1 | 2 |
| D10 | 2 |
| D14 | 2 |
| D15 | 2 |
| D3 | 2 |
| DELIRIC | 2 |
| Critically | 2 |
| DKK | 2 |
| DOASS | 2 |
| DPIA | 2 |
| DRC | 2 |
| DRKS | 2 |
| Damme | 2 |
| Critères | 2 |
| Cristina | 2 |
| Comorbidities | 2 |
| Core | 2 |
| Comparisons | 2 |
| Compensation | 2 |
| Comprehensive | 2 |
| Consortium | 2 |
| Contreras | 2 |
| Coordinator | 2 |
| Corinna | 2 |
| Creatinine | 2 |
| Cornell | 2 |
| Corp | 2 |
| Cough | 2 |
| Covidien | 2 |
| Cr | 2 |
| Creactive | 2 |
| PPE-15 | 2 |
| LoS | 2 |
| PaCO | 2 |
| l'hémostase | 2 |
| interférant | 2 |
| intégrées | 2 |
| intérêts | 2 |
| investigator(s | 2 |
| je | 2 |
| jeu | 2 |
| juridique | 2 |
| justifié | 2 |
| kg/ | 2 |
| ki | 2 |
| kin | 2 |
| l'Union | 2 |
| l'activité | 2 |
| l'atteinte | 2 |
| l'examen | 2 |
| institutional | 2 |
| initiaux | 2 |
| inhibiteurs | 2 |
| iii | 2 |
| habituelles | 2 |
| heath | 2 |
| herpès | 2 |
| homecare | 2 |
| hors | 2 |
| iCAT_SR | 2 |
| ils | 2 |
| informatique | 2 |
| imaging | 2 |
| impact | 2 |
| inattendu | 2 |
| inclura | 2 |
| inclus | 2 |
| informations | 2 |
| l'hypothèse | 2 |
| l'initiation | 2 |
| normalité | 2 |
| l'olfaction | 2 |
| medication | 2 |
| meropenem | 2 |
| mg/0.4 | 2 |
| microangiopathy | 2 |
| monitorées | 2 |
| muqueuse | 2 |
| médicale | 2 |
| médicaux | 2 |
| n=55 | 2 |
| nasal | 2 |
| nasendoscopy | 2 |
| naso | 2 |
| neuro | 2 |
| nocive | 2 |
| nom | 2 |
| mean | 2 |
| marquant | 2 |
| march | 2 |
| locale | 2 |
| l'organe | 2 |
| l'évènement | 2 |
| lettre | 2 |
| lieu | 2 |
| lipoxin | 2 |
| liée | 2 |
| logistique | 2 |
| maladie | 2 |
| lorsque | 2 |
| los | 2 |
| mL. | 2 |
| mSv | 2 |
| 2 | |
| malade | 2 |
| habituelle | 2 |
| h. | 2 |
| gsDesign | 2 |
| groupes | 2 |
| d'entraîner | 2 |
| d'identification | 2 |
| d'inclusion | 2 |
| d'opposition | 2 |
| d'étudier | 2 |
| d'être | 2 |
| data | 2 |
| day-14 | 2 |
| day-21 | 2 |
| deltamethrin | 2 |
| demandé | 2 |
| dernier | 2 |
| deux | 2 |
| diciembre | 2 |
| directement | 2 |
| d'effets | 2 |
| d'effet | 2 |
| d'autorisation | 2 |
| coordonnateur | 2 |
| connaissons | 2 |
| connue | 2 |
| consentement | 2 |
| considère | 2 |
| constaté | 2 |
| contexte | 2 |
| correspond | 2 |
| d'analyse | 2 |
| correspondance | 2 |
| corticosteroid | 2 |
| corticothérapie | 2 |
| count | 2 |
| couvertes | 2 |
| cyclooxygenase-2 | 2 |
| disease | 2 |
| dl | 2 |
| document | 2 |
| excipients | 2 |
| entraîne | 2 |
| environ | 2 |
| envoyée | 2 |
| essentiellement | 2 |
| européenne | 2 |
| examen | 2 |
| existe | 2 |
| el | 2 |
| faisons | 2 |
| final | 2 |
| française | 2 |
| garantira | 2 |
| glutamyl | 2 |
| goût | 2 |
| enregistrées | 2 |
| efficacité | 2 |
| doivent | 2 |
| décrits | 2 |
| donné | 2 |
| donnée | 2 |
| dyssynchrony | 2 |
| débuter | 2 |
| déclare | 2 |
| décrites | 2 |
| décès | 2 |
| effectuée | 2 |